Effect of combined teriparatide and monthly minodronic acid therapy on cancellous bone mass in ovariectomized rats: A bone histomorphometry study

Bone

Volumn 64, Issue , 2014, Pages 88-94

  Iwamoto, Jun ^a   Seki, Azusa ^b   Sato, Yoshihiro ^c  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HAMRI Co Ltd   (Japan)

^c Mitate Hospital   (Japan)

Author keywords

Bone histomorphometry; Cancellous bone; Minodronic acid; Ovariectomized rats; Teriparatide

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE; MINODRONIC ACID; PARATHYROID HORMONE[1-34];

ANATOMY AND HISTOLOGY; ANIMAL; BONE; DRUG COMBINATION; DRUG EFFECTS; FEMALE; ORGAN SIZE; OVARIECTOMY; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG THERAPY, COMBINATION; FEMALE; IMIDAZOLES; ORGAN SIZE; OVARIECTOMY; RATS; RATS, SPRAGUE-DAWLEY; TERIPARATIDE;

EID: 84899146503     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2014.04.003     Document Type: Article

References (21)

1. Murad M.H., Drake M.T., Mullan R.J., Mauck K.F., Stuart L.M., Lane M.A., et al. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab 2012, 97:1871-1880.
2. Black D.M., Greenspan S.L., Ensrud K.E., Palermo L., McGowan J.A., Lang T.F., et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003, 349:1207-1215.
3. Cosman F., Eriksen E.F., Recknor C., Miller P.D., Guañabens N., Kasperk C., et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res 2011, 26:503-511.
4. Tsai J.N., Uihlein A.V., Lee H., Kumbhani R., Siwila-Sackman E., McKay E.A., et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet 2013, 382:50-56.
5. Matsumoto T., Hagino H., Shiraki M., Fukunaga M., Nakano T., Takaoka K., et al. Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study. Osteoporos Int 2009, 20:1429-1437.
6. Okazaki R., Hagino H., Ito M., Sone T., Nakamura T., Mizunuma H., et al. Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis. Osteoporos Int 2012, 23:1737-1745.
7. Ebetino F.H., Hogan A.M., Sun S., Tsoumpra M.K., Duan X., Triffitt J.T., et al. The relationship between the chemistry and biological activity of the bisphosphonates. Bone 2011, 49:20-33.
8. Dunford J.E., Thompson K., Coxon F.P., Luckman S.P., Hahn F.M., Poulter C.D., et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001, 296:235-242.
9. Hagino H., Nishizawa Y., Sone T., Morii H., Taketani Y., Nakamura T., et al. A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis. Bone 2009, 44:1078-1084.
10. Eastell R., Hannon R.A., Wenderoth D., Rodriguez-Moreno J., Sawicki A. Effect of stopping risedronate after long-term treatment on bone turnover. J Clin Endocrinol Metab 2011, 96:3367-3373.
11. Confavreux C.B., Canoui-Poitrine F., Schott A.M., Ambrosi V., Tainturier V., Chapurlat R.D. Persistence at 1year of oral antiosteoporotic drugs: a prospective study in a comprehensive health insurance database. Eur J Endocrinol 2012, 166:735-741.
12. Wronski T.J., Walsh C.C., Ignaszewski L.A. Histologic evidence for osteopenia and increased bone turnover in ovariectomized rats. Bone 1986, 7:119-123.
13. Kimoto A., Tanaka M., Nozaki K., Mori M., Fukushima S., Mori H., et al. Intermittent minodronic acid treatment with sufficient bone resorption inhibition prevents reduction in bone mass and strength in ovariectomized rats with established osteopenia comparable with daily treatment. Bone 2013, 55:189-197.
14. Ma Y.L., Zeng Q.Q., Porras L.L., Harvey A., Moore T.L., Shelbourn T.L., et al. Teriparatide [rhPTH (1-34)], but not strontium ranelate, demonstrated bone anabolic efficacy in mature, osteopenic, ovariectomized rats. Endocrinology 2011, 152:1767-1778.
15. Ma Y.L., Bryant H.U., Zeng Q., Schmidt A., Hoover J., Cole H.W., et al. New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats. Endocrinology 2003, 144:2008-2015.
16. Usui T., Kamimura H. Pharmacokinetics of minodronic acid hydrate, a novel bisphosphonate, in rats and dogs. Clin Pharmacol Ther 2008, 18(Suppl. 1):S129-S142. [in Japanese].
17. Dempster D.W., Compston J.E., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2013, 28:2-17.
18. Ogawa K., Hori M., Takao R., Sakurada T. Effects of combined elcatonin and alendronate treatment on the architecture and strength of bone in ovariectomized rats. J Bone Miner Metab 2005, 23:351-358.
19. Compston J.E. Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure. Bone 2007, 40:1447-1452.
20. Zebaze R.M., Ghasem-Zadeh A., Bohte A., Iuliano-Burns S., Mirams M., Price R.I., et al. Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. Lancet 2010, 375:1729-1736.
21. Zebaze R.M., Libanati C., McClung M.R., Zanchetta J.R., Kendler D.L., Høiseth A., et al. Denosumab Reduces Hip Cortical Porosity in Women With Osteoporosis. Oral Presentation # 1065, ASBMR 2013.